Research ExplorerPublicationsLiver transplantation for metastasized extragastrointestinal...

Liver transplantation for metastasized extragastrointestinal stromal tumor

Standard

Liver transplantation for metastasized extragastrointestinal stromal tumor : a case report and an overview of literature. / Frilling, A; Malago, M; Testa, G; Schleyer, E; Grabellus, F; Kronenberger, R; Broelsch, C E.

In: TRANSPL P, Vol. 42, No. 9, 11.2010, p. 3843-8.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Frilling, A, Malago, M, Testa, G, Schleyer, E, Grabellus, F, Kronenberger, R & Broelsch, CE 2010, 'Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature', TRANSPL P, vol. 42, no. 9, pp. 3843-8. https://doi.org/10.1016/j.transproceed.2010.06.016

APA

Frilling, A., Malago, M., Testa, G., Schleyer, E., Grabellus, F., Kronenberger, R., & Broelsch, C. E. (2010). Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. TRANSPL P, 42(9), 3843-8. https://doi.org/10.1016/j.transproceed.2010.06.016

Vancouver

Frilling A, Malago M, Testa G, Schleyer E, Grabellus F, Kronenberger R et al. Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. TRANSPL P. 2010 Nov;42(9):3843-8. https://doi.org/10.1016/j.transproceed.2010.06.016

Bibtex

@article{0abc0b4116854ed996a8f99c20ef1165,
title = "Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature",
abstract = "A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.",
keywords = "Antineoplastic Agents, Benzamides, Female, Gastrointestinal Stromal Tumors, Humans, Imatinib Mesylate, Immunosuppressive Agents, Liver Neoplasms, Liver Transplantation, Living Donors, Middle Aged, Neoplasm Recurrence, Local, Piperazines, Pyrimidines, Rectal Neoplasms, Time Factors, Treatment Outcome, Vaginal Neoplasms, Case Reports, Journal Article, Review",
author = "A Frilling and M Malago and G Testa and E Schleyer and F Grabellus and R Kronenberger and Broelsch, {C E}",
note = "Crown Copyright {\textcopyright} 2010. Published by Elsevier Inc. All rights reserved.",
year = "2010",
month = nov,
doi = "10.1016/j.transproceed.2010.06.016",
language = "English",
volume = "42",
pages = "3843--8",
journal = "TRANSPL P",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "9",

}

RIS

TY - JOUR

T1 - Liver transplantation for metastasized extragastrointestinal stromal tumor

T2 - a case report and an overview of literature

AU - Frilling, A

AU - Malago, M

AU - Testa, G

AU - Schleyer, E

AU - Grabellus, F

AU - Kronenberger, R

AU - Broelsch, C E

N1 - Crown Copyright © 2010. Published by Elsevier Inc. All rights reserved.

PY - 2010/11

Y1 - 2010/11

N2 - A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.

AB - A 63-year-old woman underwent living donor liver transplantation for hepatic metastases of an extragastrointestinal stromal tumor (EGIST) originating from the rectovaginal space. Due to a multifocal extrahepatic tumor recurrence, treatment with imatinib mesylate was started after extensive pharmacokinetic studies to rule out possible interactions with immunosuppressives. We performed several re- resections for EGIST recurrence thereafter. At the last follow-up, 17 years after primary tumor resection and 10 years after living donor liver transplantation, the patient is symptom-free under immunosuppressive and imatinib mesylate treatments with a 2-cm stable recurrent pararectal EGIST. To our knowledge, this is the only report published on a patient who underwent transplantation for hepatic EGIST metastases with a posttransplantation follow-up of 10 years and the first report on living donor liver transplantation for metastasized EGIST. This is the first description of pharmacokinetics of imatinib and its main active metabolite CGP74588 in a liver transplant recipient.

KW - Antineoplastic Agents

KW - Benzamides

KW - Female

KW - Gastrointestinal Stromal Tumors

KW - Humans

KW - Imatinib Mesylate

KW - Immunosuppressive Agents

KW - Liver Neoplasms

KW - Liver Transplantation

KW - Living Donors

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Piperazines

KW - Pyrimidines

KW - Rectal Neoplasms

KW - Time Factors

KW - Treatment Outcome

KW - Vaginal Neoplasms

KW - Case Reports

KW - Journal Article

KW - Review

U2 - 10.1016/j.transproceed.2010.06.016

DO - 10.1016/j.transproceed.2010.06.016

M3 - SCORING: Review article

C2 - 21094867

VL - 42

SP - 3843

EP - 3848

JO - TRANSPL P

JF - TRANSPL P

SN - 0041-1345

IS - 9

ER -